Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
出版年份 2015 全文链接
标题
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 26, Issue suppl 5, Pages v8-v30
出版商
Oxford University Press (OUP)
发表日期
2015-08-27
DOI
10.1093/annonc/mdv298
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
- (2015) V. Bossuyt et al. ANNALS OF ONCOLOGY
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
- (2015) A. S. Coates et al. ANNALS OF ONCOLOGY
- The Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer: Perspectives for Pathologists
- (2015) Stuart J. Schnitt et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Incidence and Time Path of Lymphedema in Sentinel Node Negative Breast Cancer Patients: A Systematic Review
- (2015) Nick Gebruers et al. ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
- Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
- (2015) William M. Sikov et al. JOURNAL OF CLINICAL ONCOLOGY
- Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)
- (2015) Claudia Allemani et al. LANCET
- Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial
- (2015) Harry Bartelink et al. LANCET ONCOLOGY
- Current management of lesions associated with an increased risk of breast cancer
- (2015) Monica Morrow et al. Nature Reviews Clinical Oncology
- Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
- (2015) Sara M. Tolaney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Breast-Cancer Screening — Viewpoint of the IARC Working Group
- (2015) Béatrice Lauby-Secretan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
- (2015) Prudence A. Francis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy
- (2015) Halle C.F. Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer
- (2015) Birgitte V. Offersen et al. RADIOTHERAPY AND ONCOLOGY
- Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial
- (2014) F. Perrone et al. ANNALS OF ONCOLOGY
- First international consensus guidelines for breast cancer in young women (BCY1)
- (2014) Ann H. Partridge et al. BREAST
- Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2014) Gary H. Lyman et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
- (2014) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer
- (2014) Meena S. Moran et al. JOURNAL OF CLINICAL ONCOLOGY
- Postmastectomy radiation in breast cancer with one to three involved lymph nodes: ending the debate
- (2014) Philip Poortmans LANCET
- Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
- (2014) EBCTCG (Early Breast Cancer Trialists' Collaborative Group) LANCET
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
- (2014) Gunter von Minckwitz et al. LANCET ONCOLOGY
- Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
- (2014) Mila Donker et al. LANCET ONCOLOGY
- Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
- (2014) Robert Coleman et al. LANCET ONCOLOGY
- Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
- (2014) Olivia Pagani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic Review: Using Magnetic Resonance Imaging to Screen Women at High Risk for Breast Cancer
- (2013) Ellen Warner et al. ANNALS OF INTERNAL MEDICINE
- Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement†
- (2013) H. A. Azim et al. ANNALS OF ONCOLOGY
- Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a “standard chemotherapy regimen”: The CASA randomized trial
- (2013) Diana Crivellari et al. BREAST
- The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
- (2013) P Dubsky et al. BRITISH JOURNAL OF CANCER
- Survival after lumpectomy and mastectomy for early stage invasive breast cancer
- (2013) E. Shelley Hwang et al. CANCER
- Molecular and protein markers for clinical decision making in breast cancer: Today and tomorrow
- (2013) Nadia Harbeck et al. CANCER TREATMENT REVIEWS
- The requirements of a specialist Breast Centre
- (2013) A.R.M. Wilson et al. EUROPEAN JOURNAL OF CANCER
- An update on male breast cancer and future directions for research and treatment
- (2013) Berta Sousa et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
- (2013) C.A. Drukker et al. INTERNATIONAL JOURNAL OF CANCER
- Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer
- (2013) Judy C. Boughey JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
- (2013) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
- (2013) Aron Goldhirsch et al. LANCET
- Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial
- (2013) Jayant S Vaidya et al. LANCET
- Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial
- (2013) Umberto Veronesi et al. LANCET ONCOLOGY
- Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial
- (2013) Viviana Galimberti et al. LANCET ONCOLOGY
- 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
- (2013) Xavier Pivot et al. LANCET ONCOLOGY
- Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study
- (2013) Thorsten Kuehn et al. LANCET ONCOLOGY
- Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial
- (2013) Helena M Earl et al. LANCET ONCOLOGY
- Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98
- (2013) Elżbieta Senkus et al. PSYCHO-ONCOLOGY
- Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement
- (2012) S. Guiu et al. ANNALS OF ONCOLOGY
- Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: A meta-analysis of phase III randomized control trials
- (2012) Nan Shao et al. BREAST
- Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis
- (2012) Xiaosong Chen et al. BREAST CANCER RESEARCH AND TREATMENT
- Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
- (2012) Holm Eggemann et al. BREAST CANCER RESEARCH AND TREATMENT
- The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer
- (2012) Fatima Cardoso et al. EUROPEAN JOURNAL OF CANCER
- Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000-2002
- (2012) Claudia Allemani et al. INTERNATIONAL JOURNAL OF CANCER
- Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
- (2012) Valentina Guarneri et al. JOURNAL OF CLINICAL ONCOLOGY
- The calculation of targets for the cancer and adenoma detection rates for the NHS bowel screening programme
- (2012) Roger G Blanks et al. JOURNAL OF MEDICAL SCREENING
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- (2012) Christina Davies et al. LANCET
- FDG-PET/CT in the staging of local/regional metastases in breast cancer
- (2011) Ian J. Robertson et al. BREAST
- Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry
- (2011) Seho Park et al. BREAST
- 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques
- (2011) Bas B. Koolen et al. BREAST CANCER RESEARCH AND TREATMENT
- A population-based validation of the prognostic model PREDICT for early breast cancer
- (2011) G.C. Wishart et al. EJSO
- Association of Occult Metastases in Sentinel Lymph Nodes and Bone Marrow With Survival Among Women With Early-Stage Invasive Breast Cancer
- (2011) Armando E. Giuliano et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis
- (2011) Armando E. Giuliano JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study
- (2011) Judith M. Bliss et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
- (2011) M. Dowsett et al. JNCI-Journal of the National Cancer Institute
- HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data
- (2011) Angelo Di Leo et al. LANCET ONCOLOGY
- Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
- (2011) Meredith M Regan et al. LANCET ONCOLOGY
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial
- (2011) Erik van Werkhoven et al. RADIOTHERAPY AND ONCOLOGY
- Quality Indicators for Breast Cancer: Revisiting Historical Evidence in the Context of Technology Changes
- (2011) Philip Poortmans et al. SEMINARS IN RADIATION ONCOLOGY
- ASCO-CAP Guidelines for Breast Predictive Factor Testing
- (2011) M. Elizabeth Hale Hammond APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
- (2010) H. Eidtmann et al. ANNALS OF ONCOLOGY
- Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival
- (2010) Sylvia Adams et al. BREAST CANCER RESEARCH AND TREATMENT
- Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
- (2010) Gunter von Minckwitz et al. BREAST CANCER RESEARCH AND TREATMENT
- Locoregional treatment of primary breast cancer
- (2010) Manfred Kaufmann et al. CANCER
- Quality indicators in breast cancer care
- (2010) M. Rosselli Del Turco et al. EUROPEAN JOURNAL OF CANCER
- Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy
- (2010) Nehmat Houssami et al. EUROPEAN JOURNAL OF CANCER
- Magnetic resonance imaging of the breast: Recommendations from the EUSOMA working group
- (2010) Francesco Sardanelli et al. EUROPEAN JOURNAL OF CANCER
- American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Coprescription of Tamoxifen and Medications That Inhibit CYP2D6
- (2010) Kostandinos Sideras et al. JOURNAL OF CLINICAL ONCOLOGY
- Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations
- (2010) Larissa A. Korde et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
- (2010) Jack Cuzick et al. LANCET ONCOLOGY
- Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial
- (2010) David N Krag et al. LANCET ONCOLOGY
- Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer
- (2010) Sandhya Pruthi et al. MAYO CLINIC PROCEEDINGS
- Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationale
- (2010) Donald L Weaver MODERN PATHOLOGY
- Amenorrhea from Breast Cancer Therapy — Not a Matter of Dose
- (2010) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer
- (2010) Timothy J. Whelan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: Recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009)
- (2010) Csaba Polgár et al. RADIOTHERAPY AND ONCOLOGY
- Post-operative radiotherapy for ductal carcinoma in situ of the breast – A systematic review of the randomised trials
- (2009) Annabel Goodwin et al. BREAST
- Effect of postoperative radiotherapy on autologous deep inferior epigastric perforator flap volume after immediate breast reconstruction
- (2009) J. S. Chatterjee et al. BRITISH JOURNAL OF SURGERY
- Male breast cancer
- (2009) Laura Ottini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller
- (2009) Ana M. Gonzalez-Angulo et al. JOURNAL OF CLINICAL ONCOLOGY
- Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735
- (2009) Stephen Jones et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer
- (2009) Luca Gianni et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial
- (2009) Heikki Joensuu et al. JOURNAL OF CLINICAL ONCOLOGY
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
- (2009) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
- (2009) Kathy S Albain et al. LANCET
- Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer
- (2009) Hyman B. Muss et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
- (2009) Michael Gnant et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group
- (2008) David M. Reid et al. CANCER TREATMENT REVIEWS
- The challenges of success
- (2008) David Rew EJSO
- Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen
- (2008) Paul E. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
- (2008) Priya Rastogi et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased Risk of Recurrence After Hormone Replacement Therapy in Breast Cancer Survivors
- (2008) L. Holmberg et al. JNCI-Journal of the National Cancer Institute
- Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials
- (2008) LANCET
- The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial
- (2008) LANCET ONCOLOGY
- High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: A subgroup analysis of DBCG 82 b&c
- (2008) Marianne Kyndi et al. RADIOTHERAPY AND ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now